SHR-1702

DRUG2 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd.

Conditions

AMLAdvanced Solid TumorMDS

Phase 1

A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors

TerminatedNCT03871855

Jiangsu HengRui Medicine Co., Ltd.Advanced Solid Tumor

Start: 2019-04-28End: 2021-06-21Updated: 2023-06-05

A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

CompletedNCT04443751

Jiangsu HengRui Medicine Co., Ltd.AML, MDS

Start: 2020-09-10End: 2023-02-28Updated: 2023-08-24